Validation of analytic methods for biomarkers used in drug development

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 5967-5976

  Chau, Cindy H ^a   Rixe, Olivier ^a   McLeod, Howard ^b   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BENZOIC ACID; BIOLOGICAL MARKER; BUSULFAN; CAPECITABINE; CELECOXIB; CETUXIMAB; CEVIMELINE; DASATINIB; FLUOROURACIL; FLUOXETINE; GEFITINIB; HYDRALAZINE; IMATINIB; IRINOTECAN; ISONIAZID; LAPATINIB; LENALIDOMIDE; MARAVIROC; NILOTINIB; OLANZAPINE; OMEPRAZOLE; PANTOPRAZOLE; RETINOIC ACID; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG; VALPROIC ACID; VORICONAZOLE; WARFARIN; ANTINEOPLASTIC AGENT; PHARMACOLOGICAL BIOMARKER; TUMOR MARKER;

ANALYTIC METHOD; ASSAY; CANCER RESEARCH; CLINICAL TRIAL; DRUG RESEARCH; DRUG SENSITIVITY; GENE MUTATION; HUMAN; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; VALIDATION PROCESS; ANIMAL; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; GENOMICS; HUMAN GENOME; METABOLISM; METHODOLOGY; MOUSE; NEOPLASM; ONCOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENOME, HUMAN; GENOMICS; HUMANS; MEDICAL ONCOLOGY; MICE; NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 58149154725     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4535     Document Type: Review

References (52)

1. Park JW, Kerbel RS, Kelloff GJ, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 2004;10:3885-96.
2. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
3. Zerhouni E. Medicine. The NIH roadmap. Science 2003;302:63-72.
4. Owzar K, Barry WT, Jung S-H, Sohn I, George SL. Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res 2008;19:5959-66.
5. Taylor JMG, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res 2008;19:5977-83.
6. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008;19:5984-93.
7. George SL. Statistical issues in translational cancer research. Clin Cancer Res 2008;19:5954-8.
8. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
9. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002;18:41-6.
10. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23:312-28.
11. Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006;7:773-82.
12. Leighton JK, Brown P, Ellis A, et al. Workgroup report: Review of genomics data based on experience with mock submissions-view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee. Environ Health Perspect 2006;114:573-8.
13. Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 2007;9:E105-8.
14. Salerno RA, Lesko LJ. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 2004;5:503-5.
15. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8.
16. Lee JW, Weiner RS, Sailstad JM, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005;22:499-511.
17. Kingsmore SF. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 2006;5:310-20.
18. Ilyin SE, Belkowski SM, Plata-Salaman CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol 2004;22:411-6.
19. Miller KJ, Bowsher RR, Celniker A, et al. Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res 2001;18:1373-83.
20. Nowatzke W, Woolf E. Best practices during bioanalytical-method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J 2007;9:E117-22.
21. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991;16:249-55.
22. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000;17:1551-7.
23. Smolec J, DeSilva B, Smith W, et al. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm Res 2005;22:1425-31.
24. Colburn WA. Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 2003;43:329-41.
25. Findlay JW, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 2000;21:1249-73.
26. Lee JW, Hulse JD, Colburn WA. Surrogate biochemical markers: precise measurement for strategic drug and biologics development. J Clin Pharmacol 1995;35:464-70.
27. Lee JW, Nordblom GD, Smith WC, Bowsher RR. Validation of bioanalytical assays for novel biomarkers: practical recommendations for clinical investigation of new drug entities. In: Bloom J, editor. Biomarkers in clinical drug development. New York: Marcel Dekker; 2002.
28. Dybkaer R. Vocabulary for use in measurement procedures and description of reference materials in laboratory medicine. Eur J Clin Chem Clin Biochem 1997;35:141-73.
29. Veltri RW, Miller MC, An G. Standardization, analytical validation, and quality control of intermediate endpoint biomarkers. Urology 2001;57:164-70.
30. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. Biomarker method validation in anticancer drug development. Br J Pharmacol 2008;153:646-56.
31. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J 2007;9:E109-14.
32. Yu LR, Veenstra TD. AACR-FDA-NCI cancer biomarkers collaborative. Expert Rev Mol Diagn 2007;7:507-9.
33. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
34. Smith IE. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs 2001;12 Suppl 4:S3-10.
35. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
36. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
37. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl JMed 2001;344:783-92.
38. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
39. Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 2003;40:50-8.
40. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl JMed 2002;347:472-80.
41. Cassier PA, Dufresne A, Arifi S, et al. Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother 2008;9:1211-22.
42. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-47.
43. White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition tomonitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007;25:4445-51.
44. Wardelmann E, Buttner R, Merkelbach-Bruse S, Schildhaus HU. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 2007;451:743-9.
45. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-74.
46. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
47. Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007;38:679-87.
48. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245-66.
49. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2099-105.
50. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
51. Goncalves A, Esteyries S, Taylor-Smedra B, et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 2008;8:169.
52. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.